SCHEDULE: Armistice Capital Reports 4.99% Stake in HCW Biologics

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 353,680 shares, representing 4.99% of HCW Biologics Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed an amendment to their Schedule 13G.
• They collectively beneficially own 353,680 shares of HCW Biologics Inc. common stock.
• This ownership stake represents 4.99% of the class of securities.
• Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a disclosure of existing beneficial ownership rather than new strategic developments or financial performance.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors or individuals, often below the threshold that would trigger active control considerations. This filing suggests Armistice Capital and Steven Boyd are taking a significant, but likely passive, position in HCW Biologics Inc.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant beneficial ownership, which can inform investor sentiment and understanding of the company's shareholder base.
• Management: The disclosure may signal increased scrutiny or interest from institutional investors.

Key Dates

Keywords

Schedule 13G, HCW Biologics Inc., Armistice Capital, LLC, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing